Summit Therapeutics Inc (NAS:SMMT)

$ 17.77 -0.72 (-3.89%) Market Cap: 13.10 Bil Enterprise Value: 13.18 Bil PE Ratio: 0 PB Ratio: 30.12 GF Score: 30/100

Q3 2024 Summit Therapeutics Inc Earnings Call Transcript
Oct 30, 2024

$18.65 (-14.57%)

Earnings
Q2 2024 Summit Therapeutics Inc Earnings Call Transcript
Aug 06, 2024

$9.54 (-4.74%)

Earnings
Q1 2024 Summit Therapeutics Inc Earnings Call Transcript
May 01, 2024

$4.7 (+19.59%)

Earnings
Q4 2023 Summit Therapeutics Inc Earnings Call Transcript
Feb 20, 2024

$3.74 (-26.23%)

Earnings
Summit Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 Summit Therapeutics Inc Earnings Call Transcript
Nov 07, 2023

$1.92 (-12.16%)

Earnings
Q2 2023 Summit Therapeutics Inc Earnings Call Transcript
Aug 09, 2023

$1.94 (+10.86%)

Earnings
Q1 2023 Summit Therapeutics Inc Earnings Call Transcript
May 11, 2023

$1.93 (-9.20%)

Earnings
Summit Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Summit Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Jan 06, 2023
Summit Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Jul 27, 2022
Summit Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2022

Q4 2023 Summit Therapeutics Inc Earnings Call Transcript

Feb 20, 2024 / 02:00PM GMT

Release Date Price: $3.74 (-26.23%)

Transcript 8-K10-K

Operator

Hello, everyone. First and foremost, we'd like to apologize for the delay of this event.

Good morning, and welcome to Summit Fourth Quarter and Year End 2023 earnings call. All participants, all participants will be able to will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today for worried However, in the event that we lose the webcast connection and we are unable to provide any updates, lease rate up to 10 minutes for resolution, please refer to the company's website for updates. Please note that today's call is being recorded. (Operator Instructios)

At this time, I would like to turn the call over to Dave Gancarz, Summit Therapeutics, Chief Business and Strategy Officer. You may now proceed, please.

David Ganzarcz

Summit Therapeutics Inc - Chief Business & Strategy Officer

Good morning, and thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Our Forms 10K and S. three were also filed

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.